High levels of myocardial and hepatic triglyceride are common in obesity and type 2 diabetes. Monotherapy with thiazolidinedione agents reduces hepatic steatosis by up to 50% in patients with type 2 diabetes. It is not known if treatment with a thiazolidinedione added to insulin has a similar beneficial antisteatotic effect. The aim of our study was to determine whether the addition of pioglitazone to insulin treatment in patients with type 2 diabetes has antisteatotic action in the heart and the liver. Thirty-two patients were randomized to 6 months of treatment with insulin or insulin plus pioglitazone. In addition to blood tests, we evaluated myocardial and hepatic triglyceride content, as well as subcutaneous and visceral fat mass at the L2 level, by magnetic resonance spectroscopy and imaging, respectively. Despite weight and subcutaneous fat mass gain, hemoglobin A1c was significantly reduced by both treatments. Myocardial and hepatic triglyceride contents were reduced by the treatment with pioglitazone plus insulin (p = .02 and .03, respectively) but not by the treatment with insulin. Systolic and diastolic blood pressure and heart function remained unchanged in both groups. The addition of pioglitazone to insulin therapy reduced myocardial and hepatic steatosis, consistent with the reported ability of the thiazolidinedione agents to redistribute fat from nonadipose to subcutaneous adipose depots.
UngerRH.Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie2005;87:57–64.
3.
McGavockJM, VictorRG, UngerRH, SzczepaniakLS.Adiposity of the heart, revisited. Ann Intern Med2006;144:517–24.
4.
UngerRH.Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology2003;144:5159–65.
5.
ZhouYT, GrayburnP, KarimA. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A2000;97:1784–9.
6.
SharmaS, AdrogueJV, GolfmanL. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J2004;18:1692–700.
7.
SzczepaniakLS, BabcockEE, SchickF. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol1999;276(5 Pt 1):E977–89.
8.
CampbellPJ, CarlsonMG, NurjhanN.Fat metabolism in human obesity. Am J Physiol1994;266:E600–5.
9.
HalgrenB, StenhagenS, SvaborgA, SvennenholmL.Gas chromatographic analysis of the fatty acid composition of the plasma lipids in normal and diabetic subjects. J Clin Invest1960;39:1424–34.
10.
LaksoM, VoutilainenE, SarlundtH.Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis1985;56:271–81.
11.
BajajM, SuraamornkulS, PiperP. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab2004;89:200–6.
12.
SzczepaniakLS, NurenbergP, LeonardD. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab2005;288:E462–8.
13.
BrowningJD, SzczepaniakLS, DobbinsR. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology2004;40:1387–95.
14.
RazI, EldorR, CerneaS, ShafrirE. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev2005;21:3–14.
15.
TuomilehtoJ, LindstromJ, ErikssonJG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343–50.
16.
FreedMI, RatnerR, MarcovinaSM.Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol2002;90:947–52.
17.
BuchananTA, XiangAH, PetersRK. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes2002;51:2796–803.
18.
Yki-JarvinenH. Thiazolidinediones. N Engl J Med2004;3511106–18.
19.
BelfortR, HarrisonSA, BrownK. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med2006;355:2297–307.
20.
AnderwaldC, BernroiderE, KrssakM. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes2002;51:3025–32.
21.
SzczepaniakLS, DobbinsRL, MetzgerGJ. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med2003;49:417–23.
22.
ReingoldJS, McGavockJM, KakaS. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab2005;289:E935–9.
23.
KatzJ, MillikenMC, Stray-GundersenJ. Estimation of human myocardial mass with MR imaging. Radiology1988;169:495–8.
24.
Riley-HaganM, PeshockRM, Stray-GundersenJ. Left ventricular dimensions and mass using magnetic resonance imaging in female endurance athletes. Am J Cardiol1992;69:1067–74.
AbateN, GargA, PeshockRM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest1995;96:88–98.
27.
KankaanpaaM, LehtoHR, ParkkaJP. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab2006;91:4689–95.
28.
BrowningJD, HortonJD.Molecular mediators of hepatic steatosis and liver injury. J Clin Invest2004;114:147–52.
29.
KaserS, MoschenA, CayonA. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut2005;54:117–21.
30.
RavussinE, SmithSR.Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci2002;967:363–78.
31.
ShulmanGI.Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology2004;19:183–90.
32.
BajajM, SuraamornkulS, PratipanawatrT. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes2003;52:1364–70.
33.
OpieLH.Heart physiology: from cell to circulation. 4th ed.Lippincott Williams and Wilkins: Philadephia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo. 2004.
34.
YoungLH.Insulin resistance and the effects of thiazolidinediones on cardiac metabolism. Am J Med2003;115Suppl 8A:75S-80S.
35.
GumieniczekA.Modification of oxidative stress by pioglitazone in the heart of alloxan-induced diabetic rabbits. J Biomed Sci2005;12:531–7.
36.
Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints. Prescrire Int2005;14187–93.
37.
SharmaAM, JankeJ, GorzelniakK. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension2002;40:609–11.
38.
YuJG, JavorschiS, HevenerAL. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes2002;51:2968–74.
39.
TiikkainenM, HakkinenAM, KorsheninnikovaE. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes2004;53:2169–76.
40.
SieblerJ, GallePR.Treatment of nonalcoholic fatty liver disease. World J Gastroenterol2006;12:2161–7.
